Daniela Gompelmann1, Ralf Eberhardt, Felix Herth. 1. Pneumology and Respiratory Critical Care Medicine, Thorax Clinic at Heidelberg University Hospital, Translational Research Center Heidelberg.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is common in Germany, with a prevalence of 13.2%. The available treatments are exclusively symptomatic, except for lung transplantation, from which no more than a few patients can benefit. Over the past decade, endoscopic lung volume reduction (ELVR) has broadened the therapeutic spectrum for patients with advanced pulmonary emphysema. METHODS: We review pertinent publications that were retrieved from Pubmed using the search terms "endoscopic lung volume reduction," "endobronchial valves," "endobronchial coil," and "bronchoscopic thermal vapor ablation," along with current data from the annual meeting of the German Respiratory Society (Deutsche Gesellschaft für Pneumologie). RESULTS: ELVR is now performed with three different techniques. Endoscopic valve implantation has been studied in three randomized controlled trials (RCTs) and several noncontrolled trials, which have shown a benefit from valve therapy particularly for patients who have only a small amount of interlobar collateral ventilation or none at all. A reduction of lobar lung volume by 56-80% was found, in association with a significant improvement of lung function (a 16-26% increase of forced expiratory volume in one second [FEV1]). The main complication of valve therapy is pneumothorax, which arises in up to 23% of cases. Coil implantation has been studied to date in only a single RCT, which revealed a significant improvement in quality of life as the primary endpoint (St. George´s Respiratory Questionnaire [SGRQ]: -8 points). Bronchoscopic thermoablation has been studied only in noncontrolled intervention trials; in patients with emphysema mainly affecting the upper lobes, it has been found to reduce lobar volume by an average of 48%. CONCLUSION: Endoscopic lung volume reduction has broadened the therapeutic spectrum for selected patients with advanced pulmonary emphysema. Further prospective trials are needed to evaluate the benefits, risks, and long-term effects of the available techniques for ELVR.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is common in Germany, with a prevalence of 13.2%. The available treatments are exclusively symptomatic, except for lung transplantation, from which no more than a few patients can benefit. Over the past decade, endoscopic lung volume reduction (ELVR) has broadened the therapeutic spectrum for patients with advanced pulmonary emphysema. METHODS: We review pertinent publications that were retrieved from Pubmed using the search terms "endoscopic lung volume reduction," "endobronchial valves," "endobronchial coil," and "bronchoscopic thermal vapor ablation," along with current data from the annual meeting of the German Respiratory Society (Deutsche Gesellschaft für Pneumologie). RESULTS: ELVR is now performed with three different techniques. Endoscopic valve implantation has been studied in three randomized controlled trials (RCTs) and several noncontrolled trials, which have shown a benefit from valve therapy particularly for patients who have only a small amount of interlobar collateral ventilation or none at all. A reduction of lobar lung volume by 56-80% was found, in association with a significant improvement of lung function (a 16-26% increase of forced expiratory volume in one second [FEV1]). The main complication of valve therapy is pneumothorax, which arises in up to 23% of cases. Coil implantation has been studied to date in only a single RCT, which revealed a significant improvement in quality of life as the primary endpoint (St. George´s Respiratory Questionnaire [SGRQ]: -8 points). Bronchoscopic thermoablation has been studied only in noncontrolled intervention trials; in patients with emphysema mainly affecting the upper lobes, it has been found to reduce lobar volume by an average of 48%. CONCLUSION: Endoscopic lung volume reduction has broadened the therapeutic spectrum for selected patients with advanced pulmonary emphysema. Further prospective trials are needed to evaluate the benefits, risks, and long-term effects of the available techniques for ELVR.
Authors: Gregory Snell; Felix J F Herth; Peter Hopkins; Kimberley M Baker; Christian Witt; Mark H Gotfried; Arschang Valipour; Manfred Wagner; Franz Stanzel; Jim J Egan; Steven Kesten; Armin Ernst Journal: Eur Respir J Date: 2011-11-10 Impact factor: 16.671
Authors: Felix J F Herth; Marc Noppen; Arschang Valipour; Sylvie Leroy; Jean-Michel Vergnon; Joachim H Ficker; Jim J Egan; Stefano Gasparini; Carlos Agusti; Debby Holmes-Higgin; Armin Ernst Journal: Eur Respir J Date: 2012-01-26 Impact factor: 16.671
Authors: Daniela Gompelmann; Claus Peter Heussel; Ralf Eberhardt; Gregory Snell; Peter Hopkins; Kim Baker; Christian Witt; Arschang Valipour; Manfred Wagner; Franz Stanzel; Jim Egan; Armin Ernst; Steven Kesten; Felix J F Herth Journal: Respiration Date: 2012-03-01 Impact factor: 3.580
Authors: H Geldmacher; H Biller; A Herbst; K Urbanski; M Allison; A S Buist; J M Hohlfeld; T Welte Journal: Dtsch Med Wochenschr Date: 2008-12-03 Impact factor: 0.628
Authors: Gregory I Snell; Peter Hopkins; Glen Westall; Lynda Holsworth; Anne Carle; Trevor J Williams Journal: Ann Thorac Surg Date: 2009-12 Impact factor: 4.330
Authors: D H Sterman; A C Mehta; D E Wood; P N Mathur; R J McKenna; D E Ost; J D Truwit; P Diaz; M M Wahidi; R Cerfolio; R Maxfield; A I Musani; T Gildea; F Sheski; M Machuzak; A R Haas; H X Gonzalez; S C Springmeyer Journal: Respiration Date: 2009-11-17 Impact factor: 3.580
Authors: Eva M van Rikxoort; Jonathan G Goldin; Maya Galperin-Aizenberg; Fereidoun Abtin; Hyun J Kim; Peiyun Lu; Bram van Ginneken; Greg Shaw; Matthew S Brown Journal: Eur Radiol Date: 2011-10-08 Impact factor: 5.315
Authors: Arschang Valipour; Pallav L Shah; Wolfgang Gesierich; Ralf Eberhardt; Greg Snell; Charlie Strange; Robert Barry; Avina Gupta; Erik Henne; Sourish Bandyopadhyay; Philippe Raffy; Youbing Yin; Juerg Tschirren; Felix J F Herth Journal: Respiration Date: 2015-10-03 Impact factor: 3.580
Authors: Dominik Herzog; Alexander Poellinger; Felix Doellinger; Dirk Schuermann; Bettina Temmesfeld-Wollbrueck; Vera Froeling; Nils F Schreiter; Konrad Neumann; Stefan Hippenstiel; Norbert Suttorp; Ralf-Harto Hubner Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240